283 related articles for article (PubMed ID: 31761616)
1. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle.
Qiu B; Chen T; Sun R; Liu Z; Zhang X; Li Z; Xu Y; Zhang Z
EBioMedicine; 2019 Dec; 50():166-177. PubMed ID: 31761616
[TBL] [Abstract][Full Text] [Related]
2. Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling.
Xu YF; Liu HD; Liu ZL; Pan C; Yang XQ; Ning SL; Zhang ZL; Guo S; Yu JM
J Cell Mol Med; 2018 Nov; 22(11):5596-5606. PubMed ID: 30160357
[TBL] [Abstract][Full Text] [Related]
3. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
[TBL] [Abstract][Full Text] [Related]
4. Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.
Xu Y; Yang X; Li Z; Li S; Guo S; Ismail S; Liu H; Huang Z; Zhang Z; Chen Y; Sun Q
Oncotarget; 2017 Jan; 8(3):4888-4900. PubMed ID: 28002800
[TBL] [Abstract][Full Text] [Related]
5. Lower Expression of SPRY4 Predicts a Poor Prognosis and Regulates Cell Proliferation in Colorectal Cancer.
Zhou X; Xie S; Yuan C; Jiang L; Huang X; Li L; Chen Y; Luo L; Zhang J; Wang D; Liu L; Shi W; Han L; Tang N; Ji Y
Cell Physiol Biochem; 2016; 40(6):1433-1442. PubMed ID: 27997895
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
8. Suppression of SPRY4 Promotes Osteogenic Differentiation and Bone Formation of Mesenchymal Stem Cell.
Park S; Arai Y; Kim BJ; Bello A; Ashraf S; Park H; Park KS; Lee SH
Tissue Eng Part A; 2019 Dec; 25(23-24):1646-1657. PubMed ID: 30982407
[TBL] [Abstract][Full Text] [Related]
9. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
10. Sprouty 4 suppresses glioblastoma invasion by inhibiting ERK phosphorylation and ETS-1-induced matrix metalloproteinase-9.
Zhao B; Sun J; DU K; Liang N; Sun J
J Neurosurg Sci; 2023 Feb; 67(1):121-128. PubMed ID: 32618153
[TBL] [Abstract][Full Text] [Related]
11. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Int J Cancer; 2015 Aug; 137(3):560-70. PubMed ID: 25630587
[TBL] [Abstract][Full Text] [Related]
12. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
[TBL] [Abstract][Full Text] [Related]
13. PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Sun R; Chen T; Li M; Liu Z; Qiu B; Li Z; Xu Y; Pan C; Zhang Z
Biomed Pharmacother; 2020 Jan; 121():109583. PubMed ID: 31706106
[TBL] [Abstract][Full Text] [Related]
14. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
15. Spry1 and Spry2 are necessary for eyelid closure.
Kuracha MR; Siefker E; Licht JD; Govindarajan V
Dev Biol; 2013 Nov; 383(2):227-38. PubMed ID: 24055172
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
Hu X; Tan Z; Yang Y; Yang P
J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1.
Liu Z; Sun R; Zhang X; Qiu B; Chen T; Li Z; Xu Y; Zhang Z
EBioMedicine; 2019 Jul; 45():181-191. PubMed ID: 31248836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
